| Literature DB >> 35862997 |
Iñigo Arberas-Jiménez1,2,3, Aitor Rizo-Liendo1,2,3, Ines Sifaoui1,2,3, Javier Chao-Pellicer1,2,3, José E Piñero1,2,3,4, Jacob Lorenzo-Morales1,2,3,4.
Abstract
Primary amoebic meningoencephalitis (PAM) is a lethal and rapid infection that affects the central nervous system and is caused by the free-living amoeba Naegleria fowleri. The life cycle of this protozoa consists of three different stages: The trophozoite, flagellate and cyst stages. Currently, no fully effective molecules have been found to treat PAM. In the search of new antiamoebic molecules, most of the efforts have focused on the trophozoidal activity of the compounds. However, there are no reports on the effect of the compounds on the N. fowleri cyst viability. In the present study, the cysticidal activity of four different molecules was evaluated using an alamarBlue based fluorometric assay. All the tested compounds were active against the cyst stage of N. fowleri. In fact, all the molecules except the amphotericin B, showed highest activity toward the cyst stage than the trophozoite stage. This work could be an effective protocol to select molecules with cysticidal and trophozoidal activity that can be considered a future PAM treatment. IMPORTANCE In the search of new anti-Naegleria fowleri compounds, most of the works focus on the activity of different molecules against the trophozoite stage; however, none of them include the effect of those compounds on the cyst viability. This manuscript presents a solid and reliable assay to evaluate the activity of compounds against the cyst stage of N. fowleri.Entities:
Keywords: Naegleria; antiamoebic activity; cyst; meningoencephalitis; protocol
Mesh:
Year: 2022 PMID: 35862997 PMCID: PMC9430148 DOI: 10.1128/spectrum.00515-22
Source DB: PubMed Journal: Microbiol Spectr ISSN: 2165-0497
Inhibitory concentrations 50 (IC50) of evaluated compounds against cyst and trophozoite stage of Naegleria fowleri ATCC 30808 strain
| Compound | IC50 (μM) against cyst stage | IC50 (μM) against trophozoite stage |
|---|---|---|
| Staurosporine | 0.06 ± 0.01 | 0.08 ± 0.01 |
| Laurinterol | 8.81 ± 1.08 | 13.42 ± 2.57 |
| Amphotericin b | 0.53 ± 0.03 | 0.12 ± 0.03 |
| Miltefosine | 21.52 ± 2.62 | 38.74 ± 4.23 |
Experiments were made in triplicate in three different and independent assays and the mean values and standard deviation were also calculated.
FIG 1Dose-response assessment for each drug against N. fowleri cysts after 96 h. Bars represent the trophozoite growth (estimated by the resazurin reduction) after the excystation, thus the percentage of cysts that remain viable after the treatment is measured. Experiments were made in triplicate in three different and independent assays and the mean values and standard deviations were also calculated. Differences between the values were assessed using one-way analysis of variance (ANOVA). Data are presented as means ± SD. NS, not significant; *, P value < 0.05; **, P value < 0.01; ***, P value < 0.001; ****, P value <0.0001.
FIG 2N. fowleri cysts after 24 h of incubation with the evaluated compounds. Staurosporine (B) at 0.26 μM, laurinterol at 10.58 μM (C), amphotericin B (D) at 1.35 μM and miltefosine (E) at 36.80 μM. Negative control (A) consisted of the cysts with bactocasitone. Images (40 ×) were obtained using an EVOS M5000 Cell Imaging System, Life Technologies, Spain. Scale bar, 75 μm.